{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:04:40Z","timestamp":1779761080765,"version":"3.53.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2023GXNSFBA026007"],"award-info":[{"award-number":["2023GXNSFBA026007"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260469"],"award-info":[{"award-number":["82260469"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102710"],"award-info":[{"award-number":["82102710"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the First Batch of the Guangxi Zhuang Autonomous Region Medical Young Reserve Talent Training Program","award":["the First Batch of the Guangxi Zhuang Autonomous Region Medical Young Reserve Talent Training Program (China)"],"award-info":[{"award-number":["the First Batch of the Guangxi Zhuang Autonomous Region Medical Young Reserve Talent Training Program (China)"]}]},{"name":"the 2024 Innovation-Driven Talent Program for First-Class Disciplines of Guangxi Medical University","award":["the 2024 Innovation-Driven Talent Program for First-Class Disciplines of Guangxi Medical University (China)"],"award-info":[{"award-number":["the 2024 Innovation-Driven Talent Program for First-Class Disciplines of Guangxi Medical University (China)"]}]},{"name":"the 2025 Outstanding Young Talent Training Program of the First Affiliated Hospital of Guangxi Medical University","award":["the 2025 Outstanding Young Talent Training Program of the First Affiliated Hospital of Guangxi Medical University (China)"],"award-info":[{"award-number":["the 2025 Outstanding Young Talent Training Program of the First Affiliated Hospital of Guangxi Medical University (China)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08112-2","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:48:58Z","timestamp":1775832538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IGFBP2 promotes immunosuppression by regulating macrophage PD-L1 expression in NEUROD1-high small cell lung cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Siyi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rensheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"3","key":"8112_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"MLAVERSANNE F BRAY","year":"2024","unstructured":"Bray F, Laversanne M. Global cancer statistics 2022: GLOBOCAN estimates ofincidence and mortality worldwide for 36 cancers in 185 countries [J]. CancerJ Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"1","key":"8112_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"EBRAMBILLA C M RUDIN","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer [J]. Natreviews Disease primers. 2021;7(1):3.","journal-title":"Nat reviews Disease primers"},{"issue":"7","key":"8112_CR3","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/cncr.34074","volume":"128","author":"LIU L LIANG, Z","year":"2022","unstructured":"Liang L, Liu Z, Zhu H. Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial [J]. Cancer. 2022;128(7):1467\u201374.","journal-title":"Cancer"},{"issue":"Pt 2","key":"8112_CR4","first-page":"543","volume":"86","author":"JM W Z WANG, A SHULMAN","year":"2022","unstructured":"Wang WZ, Shulman A, Amann JM, et al. Small cell lung cancer: subtypes and therapeutic implications [J]. Sem Cancer Biol. 2022;86(Pt 2):543\u201354.","journal-title":"Sem Cancer Biol"},{"issue":"23","key":"8112_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"ASZCZ\u0118SNA L HORN, A S MANSFIELD","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer [J]. N Engl J Med. 2018;379(23):2220\u20139.","journal-title":"N Engl J Med"},{"issue":"10212","key":"8112_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"MDVORKIN L PAZ-ARES","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al. plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J]. Lancet (London England). 2019;394(10212):1929\u201339.","journal-title":"Lancet (London England)"},{"issue":"14","key":"8112_CR7","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/jnci\/djt130","volume":"105","author":"IDOBROMILSKAYA J T POIRIER","year":"2013","unstructured":"Poirier JT, Dobromilskaya I, Moriarty WF, et al. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer [J]. J Natl Cancer Inst. 2013;105(14):1059\u201365.","journal-title":"J Natl Cancer Inst"},{"issue":"43","key":"8112_CR8","doi-asserted-by":"publisher","first-page":"73745","DOI":"10.18632\/oncotarget.20572","volume":"8","author":"GWILDEY K MCCOLL","year":"2017","unstructured":"McColl K, Wildey G. Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer [J]. Oncotarget. 2017;8(43):73745\u201356.","journal-title":"Oncotarget"},{"key":"8112_CR9","doi-asserted-by":"crossref","unstructured":"Huang YH, Klingbeil O, He XY, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer [J]. Genes Dev. 2018;32:13\u201314.","DOI":"10.1101\/gad.314815.118"},{"issue":"5","key":"8112_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"C M RUDIN","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data [J]. Nat Rev Cancer. 2019;19(5):289\u201397.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"8112_CR11","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"M K BAINE","year":"2020","unstructured":"Baine MK, Hsieh MS, Lai WV, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization [J]. J Thorac Oncology: official publication Int Association Study Lung Cancer. 2020;15(12):1823\u201335.","journal-title":"J Thorac oncology: official publication Int Association Study Lung Cancer"},{"key":"8112_CR12","doi-asserted-by":"crossref","unstructured":"Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities [J]. Cancer Cell. 2021;39(3): 346\u2009\u2013\u200960.e7.","DOI":"10.1016\/j.ccell.2020.12.014"},{"issue":"1","key":"8112_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13027-023-00543-6","volume":"18","author":"Y X CHEN","year":"2023","unstructured":"Chen X, Zhang Y, Zhang P, et al. IGFBP2 drives epithelial-mesenchymal transition in hepatocellular carcinoma via activating the Wnt\/\u03b2-catenin pathway [J]. Infect agents cancer. 2023;18(1):73.","journal-title":"Infect agents cancer"},{"key":"8112_CR14","doi-asserted-by":"crossref","unstructured":"Lu HJ, Zheng Y, et al. IGFBP2\/ITGA5 promotes gefitinib resistance via activating STAT3\/CXCL1 axis in non-small cell lung cancer [J]. Cell Death Dis. 2024;15:447(6).","DOI":"10.1038\/s41419-024-06843-y"},{"issue":"1","key":"8112_CR15","doi-asserted-by":"publisher","first-page":"C252","DOI":"10.1152\/ajpcell.00234.2023","volume":"326","author":"SUN X ZHANG, X","year":"2024","unstructured":"Zhang X, Sun X, Guo C, et al. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization [J]. Am J Physiol Cell Physiol. 2024;326(1):C252\u201368.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"8112_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/path.4734","volume":"239","author":"L M PHILLIPS","year":"2016","unstructured":"Phillips LM, Zhou X, Cogdell DE, et al. Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies [J]. J Pathol. 2016;239(3):355\u201364.","journal-title":"J Pathol"},{"key":"8112_CR17","doi-asserted-by":"crossref","unstructured":"Wen ZH, Zhang Z, et al. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway [J]. Cancer Commun (Lond). 2023;43(5):562\u2013581.","DOI":"10.1002\/cac2.12420"},{"key":"8112_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2020.02.036","volume":"477","author":"ZHANG T LI, C","year":"2020","unstructured":"Li T, Zhang C, Zhao G. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma [J]. Cancer Lett. 2020;477:19\u201330.","journal-title":"Cancer Lett"},{"issue":"8","key":"8112_CR19","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"LAKKARI D J KLOOSTERMAN","year":"2023","unstructured":"Kloosterman DJ, Akkari L. Macrophages at the interface of the co-evolving cancer ecosystem [J]. Cell. 2023;186(8):1627\u201351.","journal-title":"Cell"},{"key":"8112_CR20","doi-asserted-by":"crossref","unstructured":"Wang J, Mi S, Ding M, et al. Metabolism and polarization regulation of macrophages in the tumor microenvironment. Cancer Lett. 2022;543:215766.","DOI":"10.1016\/j.canlet.2022.215766"},{"issue":"7","key":"8112_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"FMARCHESI A MANTOVANI","year":"2017","unstructured":"Mantovani A, Marchesi F. Tumour-associated macrophages as treatment targets in oncology [J]. Nat reviews Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat reviews Clin Oncol"},{"issue":"11","key":"8112_CR22","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","volume":"39","author":"JMCHAN \u00c1 QUINTANAL-VILLALONGA","year":"2021","unstructured":"Chan JM, Quintanal-Villalonga \u00c1, Gao VR, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer [J]. Cancer Cell. 2021;39(11):1479\u2013e9618.","journal-title":"Cancer Cell"},{"issue":"4","key":"8112_CR23","doi-asserted-by":"publisher","first-page":"e1005895","DOI":"10.1371\/journal.pgen.1005895","volume":"12","author":"JHUANG L JIANG","year":"2016","unstructured":"Jiang L, Huang J, Higgs BW, et al. Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer [J]. PLoS Genet. 2016;12(4):e1005895.","journal-title":"PLoS Genet"},{"issue":"34","key":"8112_CR24","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1038\/s41388-025-03481-2","volume":"44","author":"YOKABE H TAKUMIDA, A SAITO","year":"2025","unstructured":"Takumida H, Saito A, Okabe Y, et al. Integrative epigenome and transcriptome analyses reveal transcriptional programs differentially regulated by ASCL1 and NEUROD1 in small cell lung cancer [J]. Oncogene. 2025;44(34):3113\u201325.","journal-title":"Oncogene"},{"key":"8112_CR25","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/srep01911","volume":"3","author":"STSUJI T SATO, A KANEDA","year":"2013","unstructured":"Sato T, Kaneda A, Tsuji S, et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer [J]. Sci Rep. 2013;3:1911.","journal-title":"Sci Rep"},{"issue":"45","key":"8112_CR26","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.3346\/jkms.2023.38.e381","volume":"38","author":"SS YOO","year":"2023","unstructured":"Yoo SS, Lee S, Choi JE, et al. Promoter-specific variants in NeuroD1 and H3K4me3 coincident regions and clinical outcomes of small cell lung cancer [J]. J Korean Med Sci. 2023;38(45):e381.","journal-title":"J Korean Med Sci"},{"key":"8112_CR27","doi-asserted-by":"publisher","first-page":"1146981","DOI":"10.3389\/fbioe.2023.1146981","volume":"11","author":"JWANG Q WEI","year":"2023","unstructured":"Wang J, Wei Q. Small extracellular vesicles derived from four dimensional-culture of mesenchymal stem cells induce alternatively activated macrophages by upregulating IGFBP2\/EGFR to attenuate inflammation in the spinal cord injury of rats [J]. Front Bioeng Biotechnol. 2023;11:1146981.","journal-title":"Front Bioeng Biotechnol"},{"key":"8112_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.canlet.2020.12.008","volume":"500","author":"LSUN X","year":"2021","unstructured":"Sun L, Zhang X, Song Q, et al. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway [J]. Cancer Lett. 2021;500:132\u201346.","journal-title":"Cancer Lett"},{"issue":"1","key":"8112_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"JWPOLLARD B Z QIAN","year":"2010","unstructured":"Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis [J]. Cell. 2010;141(1):39\u201351.","journal-title":"Cell"},{"key":"8112_CR30","first-page":"55","volume":"7","author":"ACHIANG Y NIE, K A SCHALPER","year":"2024","unstructured":"Nie Y, Schalper KA, Chiang A. Mechanisms of immunotherapy resistance in small cell lung cancer [J]. Cancer drug Resist (Alhambra Calif). 2024;7:55.","journal-title":"Cancer drug Resist (Alhambra Calif)"},{"key":"8112_CR31","doi-asserted-by":"crossref","unstructured":"Nabet BY, Hamidi MC, Lee, et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024;42(3):429\u2013443.e4.","DOI":"10.1016\/j.ccell.2024.01.010"},{"issue":"16","key":"8112_CR32","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","volume":"187","author":"CARDELLO A R CILLO, C","year":"2024","unstructured":"Cillo AR, Cardello C, Shan F, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity [J]. Cell. 2024;187(16):4373\u2013e8815.","journal-title":"Cell"},{"issue":"3","key":"8112_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00281-019-00744-5","volume":"41","author":"M KURACHI","year":"2019","unstructured":"Kurachi M. CD8(+) T cell exhaustion [J]. Semin Immunopathol. 2019;41(3):327\u201337.","journal-title":"Semin Immunopathol"},{"issue":"5","key":"8112_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1210\/endrev\/bnad008","volume":"44","author":"R C BAXTER","year":"2023","unstructured":"Baxter RC. Signaling pathways of the insulin-like growth factor binding proteins [J]. Endocr Rev. 2023;44(5):753\u201378.","journal-title":"Endocr Rev"},{"issue":"29","key":"8112_CR35","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/s41388-021-01907-1","volume":"40","author":"BAILEY Y LIU, M V NELSON, C","year":"2021","unstructured":"Liu Y, Nelson MV, Bailey C, et al. Targeting the HIF-1\u03b1-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor [J]. Oncogene. 2021;40(29):4809\u201319.","journal-title":"Oncogene"},{"key":"8112_CR36","doi-asserted-by":"crossref","unstructured":"Komisarof J, McCall M, Newman L, et al. A four gene signature predictive of recurrent prostate cancer. Oncotarget. 2017;8(2):3430\u20133440.","DOI":"10.18632\/oncotarget.13837"},{"issue":"5","key":"8112_CR37","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/onc.2012.630","volume":"33","author":"SZIVKOVIC W J AZAR","year":"2014","unstructured":"Azar WJ, Zivkovic S, Werther GA, et al. IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells [J]. Oncogene. 2014;33(5):578\u201388.","journal-title":"Oncogene"},{"issue":"1","key":"8112_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13059-021-02322-1","volume":"22","author":"A PANIGRAHI","year":"2021","unstructured":"Panigrahi A, O'Malley BW. Mechanisms of enhancer action: the known and the unknown [J]. Genome Biol. 2021;22(1):108.","journal-title":"Genome Biol"},{"issue":"4","key":"8112_CR39","first-page":"650","volume":"172","author":"S A LAMBERT","year":"2018","unstructured":"Lambert SA, Jolma A, Campitelli LF, et al. Hum transcription factors [J]. Cell. 2018;172(4):650\u201365.","journal-title":"Hum Transcription Factors [J] Cell"},{"issue":"6","key":"8112_CR40","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3322\/caac.21785","volume":"73","author":"HPOPPER Z MEGYESFALVI, C M GAY","year":"2023","unstructured":"Megyesfalvi Z, Gay CM, Popper H, et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions [J]. Cancer J Clin. 2023;73(6):620\u201352.","journal-title":"Cancer J Clin"},{"key":"8112_CR41","doi-asserted-by":"publisher","first-page":"1191855","DOI":"10.3389\/fonc.2023.1191855","volume":"13","author":"RRITTBERG D E DAWE","year":"2023","unstructured":"Dawe DE, Rittberg R, Syed I, et al. Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study [J]. Front Oncol. 2023;13:1191855.","journal-title":"Front Oncol"},{"issue":"1","key":"8112_CR42","doi-asserted-by":"publisher","first-page":"14947","DOI":"10.1038\/s41598-023-41972-y","volume":"13","author":"M M LIANG","year":"2023","unstructured":"Liang M, Chen M, Singh S, et al. Identification of a visualized web-based nomogram for overall survival prediction in patients with limited stage small cell lung cancer [J]. Sci Rep. 2023;13(1):14947.","journal-title":"Sci Rep"},{"issue":"5","key":"8112_CR43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/onco.13752","volume":"26","author":"LMATHIEUSSHAH L PAI-SCHERF","year":"2021","unstructured":"Mathieu L, Shah S, Pai-Scherf L, et al. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer [J]. Oncologist. 2021;26(5):433\u20138.","journal-title":"Oncologist"},{"issue":"7","key":"8112_CR44","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.7150\/thno.52435","volume":"11","author":"FZHANG X CHEN, A GAO","year":"2021","unstructured":"Chen X, Gao A, Zhang F, et al. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation [J]. Theranostics. 2021;11(7):3392\u2013416.","journal-title":"Theranostics"},{"key":"8112_CR45","doi-asserted-by":"crossref","unstructured":"Yamaguchi Y, Gibson J, Ou K, et al. PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163\u2009+\u2009M2 macrophages [J]. J Immunother Cancer. 2022;10(6).","DOI":"10.1136\/jitc-2021-004400"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08112-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08112-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08112-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:01:19Z","timestamp":1779760879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08112-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8112"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08112-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of human specimens in this study was approved by the Ethics Committee of Guangxi Zhuang Autonomous Region Ethnic Hospital (Approval No.:2025\u2009\u2212\u2009100 ). The study was conducted in accordance with the ethical standards of the Declaration of Helsinki. Informed consent was obtained from all participants in accordance with the regulations. The consent process for human participants included a detailed explanation of the study\u2019s purpose, procedures, risks, benefits, and confidentiality measures. The use of animal specimens in this study was approved by the Animal Experimental Ethics Committee of Guangxi Medical University (Approval No.: 202401028). All animal procedures were performed in accordance with the ethical standards of the institution and adhere to the guidelines set forth by the National Health Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare no conflicts of interest in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"697"}}